Eris Lifesciences to acquire remaining 30% in Swiss Parenterals for ₹423 crore

Eris Lifesciences Ltd has moved to fully consolidate its injectable manufacturing subsidiary, Swiss Parenterals, by acquiring the remaining 30% stake for ₹423.3 crore, the company told stock exchanges

on Monday. Eris currently holds 70% in Swiss.

The consideration will be discharged entirely through a share swap, with Eris proposing to issue 23,06,372 equity shares on a preferential basis to Naishadh Shah, a director at Swiss Parenterals and the seller of the stake, according to the filing. The issue price has been set at ₹1,835.35 per share, as determined by an independent valuation.

Following the acquisition, Swiss Parenterals will become a wholly owned subsidiary. Eris said the buyout is aimed at strengthening operational control, improving cost efficiencies and enabling full financial consolidation. The deal is expected to close before 31 March 2026, subject to customary approvals.

Swiss Parenterals, incorporated in 1997, manufactures parenteral products and supplies to over 80 countries. The entity reported a turnover of ₹351 crore in FY25, up from ₹283 crore in FY24 and ₹221 crore in FY23.

Separately, Eris will seek shareholder approval via postal ballot for the preferential allotment and for approval of the related-party transaction, given Shah’s role at the subsidiary. The cut-off date for voting has been set as 21 November 2025.

Ahead of the announcement, shares of Eris Lifesciences closed at ₹1,653.20, down 0.77% on the NSE.